Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Surmodics (SRDX)
NASDAQ:SRDX
Holding SRDX?
Track your performance easily
Earnings Data
Report Date
Jan 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.12Last Year’s EPS
0Same Quarter Last Year
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 09, 2018
|% Change Since: -2.07%
|Next Earnings Date:Aug 06, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and profitability improvements, driven by the Medical Device segment and successful product launches. However, challenges remain in the IVD segment and product gross margins. The sentiment is positive due to the significant achievements outweighing the challenges.Company Guidance
During Surmodics' second quarter fiscal year 2024 earnings call, the company reported strong financial performance and updated its guidance for the year. Total revenue for the quarter grew by 18% year-over-year to $32 million, with a notable 26% increase in the Medical Device segment to $24.8 million. Excluding the SurVeil drug-coated balloon license fee, revenue grew by 19%. The company achieved an $8 million improvement from a GAAP net loss to GAAP net income and a $6.3 million rise in adjusted EBITDA. Surmodics' cash flow from operations reached $7.4 million, bolstered by $1.4 million in royalty catch-up payments and a $3.4 million cash tax refund. For fiscal 2024, Surmodics raised its revenue guidance to $122-$124 million, indicating a 15%-17% increase excluding SurVeil license fees, and improved its non-GAAP loss per share outlook to a range of $0.67-$0.47. The company attributed its success to robust sales of its Vascular Interventions portfolio, including SurVeil, Pounce thrombectomy, and Sublime radial access products, and highlighted ongoing operational progress towards strategic objectives, such as launching new products and advancing clinical evaluations.Strong Revenue Growth
Total revenue increased by 18% year-over-year to $32 million, with a significant contribution from the Medical Device segment, which grew by 26% to $24.8 million.
Medical Device Segment Success
Product sales in the Medical Device segment increased by 40% year-over-year, driven by the Vascular Interventions portfolio, including SurVeil DCB, Pounce thrombectomy, and Sublime radial access products.
Profitability Improvements
Achieved an $8 million improvement from a GAAP net loss to GAAP net income and a $6.3 million increase in adjusted EBITDA.
Successful Product Launches
Completed limited market evaluations and launched Pounce venous and Pounce low profile thrombectomy systems.
Positive Cash Flow
Generated $7.4 million in cash flow from operations, driven by royalty catch-up payments and a $3.4 million cash tax refund.
---
SRDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SRDX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $37.66 | $38.49 | +2.20% |
| Jul 31, 2024 | $41.50 | $41.40 | -0.24% |
| May 01, 2024 | $25.69 | $33.33 | +29.74% |
| Feb 01, 2024 | $35.21 | $32.43 | -7.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Surmodics (SRDX) report earnings?
Surmodics (SRDX) is schdueled to report earning on Jan 30, 2025, TBA Not Confirmed.
What is Surmodics (SRDX) earnings time?
Surmodics (SRDX) earnings time is at Jan 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SRDX EPS forecast?
SRDX EPS forecast for the fiscal quarter 2025 (Q1) is -0.12.
---